Body Image and GLP-1s: What the Drugs Don't Fix

Here is the uncomfortable thing nobody in the GLP-1 conversation wants to say out loud: the drug can change your body, but it cannot change what you see when you look in the mirror.

That gap—between the body you have and the body you experience yourself as having—is where a lot of people are quietly struggling right now. And it's increasingly where psychologists are focusing their attention.

The drug works. The mirror doesn't always update.

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have reshaped the clinical conversation around weight in ways that would have seemed implausible five years ago. The weight loss numbers are real, the demand is real, and the cultural moment is unmistakably real.

What's also real, and less discussed: the psychological experience doesn't necessarily track the physical one.

According to a peer-reviewed paper on ScienceDirect, GLP-1s may influence body image in ways that are neurobiologically distinct from other weight-loss interventions—because unlike behavioral approaches, these medications act directly on neurobiological systems related to appetite, reward, and satiety. The researchers flag this as a significant open question: if the drug is changing the brain's reward circuitry around food, what does that mean for how people process their own appearance, their sense of control, their self-concept? The researchers frame these as "emerging questions for research and practice"—which is academic for we genuinely don't know yet.

That uncertainty matters. Because we have tens of millions of people on these medications, and the psychological infrastructure for understanding what they're experiencing is still being built.

What GLP-1s haven't touched

Psychology Today puts it plainly: there are things GLP-1s simply have not changed. The internal critic. The habitual self-surveillance. The way someone who spent decades at war with their body doesn't suddenly call a truce because a medication changed a number on a scale.

This is not a failure of the drugs. It's a failure of the assumption that body image distress is primarily about body size—that if you remove the size, the distress follows. The clinical literature on this has been consistent for decades. Body image is a psychological construct, not a physical measurement. It's possible to lose significant weight and feel worse about your body. It's also possible to gain weight and feel fine. The two things are related but not the same thing.

The Baltimore Therapy Group addresses this directly, noting that some people using GLP-1s report persistent body image concerns even as their weight changes—and that for people with histories of disordered eating or body dysmorphia, the medications can sometimes intensify preexisting psychological patterns rather than resolve them. That's a clinically significant observation, and it's one worth sitting with before assuming the drug is a complete solution.

The cultural collision nobody planned for

Here's the structural tension underneath all of this, and it's genuinely unresolved.

The body positivity movement spent roughly a decade building a cultural argument that bodies don't need to be fixed—that the problem is shame, not size, and that self-acceptance is both the goal and the method. That argument gained real traction. It changed how brands marketed to women, how clinicians were trained to talk about weight, how diet culture got named and critiqued.

Then GLP-1s arrived.

Rutgers-Camden researcher Charlotte Markey put the collision into words clearly. As reported by Rutgers University-Camden, Markey observed: "On one hand, the body positivity movement encourages self-acceptance, respect for body diversity, and a rejection of the shame-based messages that have harmed people for generations. On the other hand, the rapid rise of GLP-1 medications has revived a cultural obsession" with rapid weight loss.

That's not a solvable tension, at least not cleanly. The medications are not inherently incompatible with self-acceptance—someone can use a GLP-1 for genuine health reasons and also hold their body with some degree of care. But at the cultural level, the framing has not been subtle. The Ozempic conversation has been saturated with before-and-after imagery, celebrity weight speculation, and a renewed normalization of the premise that smaller is straightforwardly better. Women's Health noted directly that despite whatever individual benefits GLP-1s may provide, "the overall cultural fixation on rapid weight loss isn't healthy"—which is a different claim than whether the drugs themselves are.

Diana Hill's intervention, and where it fits

This is where psychologist Diana Hill's work lands, and it's worth understanding what she is and isn't arguing.

As NPR reported, Hill advocates for what she calls "body image flexibility"—a frame that shifts attention from how the body looks to what it can do. The mental exercises she recommends are designed to build an appreciation of the body as an instrument of experience rather than an object of evaluation. Can you walk somewhere that matters to you? Does your body let you hug someone, make food, feel sun? The pivot is from appearance-based self-assessment toward function-based appreciation.

This framework sits within a broader tradition in clinical psychology—Acceptance and Commitment Therapy (ACT) and similar approaches have been using functional framing for body image work for years. Hill's contribution seems to be making it accessible and applying it explicitly to this cultural moment.

What makes it interesting here is the specificity of the target. Hill is not arguing against GLP-1 use. She's addressing the psychological experience of living in a body during a period of intensified cultural scrutiny—whether or not you're on the medication. The advice is useful precisely because the underlying problem (appearance-focused self-evaluation in an image-saturated environment) exists independent of any particular drug.

Gateway to Solutions flags a related and often underappreciated dimension: the role of stress and daily habit in body image experience. Their guidance points toward small daily practices—noticing what went well, reframing negative thoughts in the moment, finding functional joy in ordinary physical experience—as meaningful scaffolding. None of that is glamorous advice. It's also the kind of thing that actually compounds over time.

The open question worth sitting with

Here's what I keep coming back to: GLP-1s are, in a clinical sense, the most effective pharmacological weight-loss tools we've had. That's a factual statement. And simultaneously, the psychological research on body image makes pretty clear that appearance satisfaction is not primarily a function of appearance. It's a function of relationship—to yourself, to your body, to the standards you've internalized.

A medication can change your weight. It cannot change what those standards are or where they came from.

So the practical question isn't whether GLP-1s are good or bad—that's too blunt an instrument for a genuinely complex pharmacological and social development. The more useful question is: what psychological work runs alongside the medical intervention? And what happens to people who take the drug without ever addressing the part of the problem the drug can't reach?

The researchers, the clinicians, and the psychologists working in this space are all pointing at the same gap. We just haven't decided, culturally, whether we want to look at it.